Protagonist Therapeutics

Today the FDA approved ICOTYDE™ (icotrokinra), the first targeted oral peptide option for first-line systemic treatment of plaque psoriasis. This milestone reflects the power of our science and platform. Thank you to the PTGX team, Johnson & Johnson, investigators and patients who made it possible. Read more: bit.ly/4sckfLP

Happy International Women's Day! This year's theme, #GiveToGain, encourages a mindset of generosity and collaboration in support of women's advancement to create a better future for all. We are proud of our Protagonist team for exemplifying this sentiment and celebrate their successes and contributions as we pursue our mission to improve patient lives. #IWD2026

Today, Protagonist and Takeda announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for rusfertide, an investigational, first-in-class hepcidin mimetic peptide therapeutic for the treatment of adults with polycythemia vera (PV). Read more details in our latest press release: feeds.issuerdirect.com/news-release.h…

Today is #RareDiseaseDay! 300 million people worldwide live with a rare disease and each one of their journeys is unique, as represented by our employees' zebra cookie creations. From diagnostic odysseys to lack of approved treatments, those affected by rare diseases face numerous challenges that must be addressed with scientific innovation, ongoing advocacy, and increased awareness. At Protagonist Therapeutics, patient stories and hope inspire what we do every day as we work towards bringing groundbreaking solutions and a brighter future for those living with polycythemia vera (PV).

As communities gather worldwide to recognize #RareDiseaseDay on February 28th, we asked our Vice President of Clinical Ops, Antonieta Sosa, what moments in her work reinforce the importance of what we do for patients living with a rare disease like polycythemia vera (PV).

Today, we reported financial results for the fourth quarter and full year 2025 and provided a corporate update. See the full press release here: bit.ly/4aWIXIL

Our President and @ProtagonistCEO, Dinesh V. Patel, PhD, will participate in multiple investment bank conferences taking place this March. Access these webcasts in our latest press release: bit.ly/4kXb92L

According to the National Organization for Rare Disorders (@RareDiseases), over 1 in 4 cancer diagnoses in the U.S. are rare, and the 5-year survival rate is lower for people living with a rare cancer compared those diagnosed with a more common cancer. No matter how big or small, every action to raise awareness can help make a difference in the lives of patients and their loved ones. Ahead of Rare Disease Day on February 28th, we're shining a spotlight on polycythemia vera (PV).

Full video: biotechtv.com/post/protagoni…

It was great to show @BiotechTV's @bradloncar around our lab as our @ProtagonistCEO, Dinesh V. Patel, PhD, and Chief Discovery Officer, Ashok Bhandari, PhD, discussed our pioneering peptide technology platform and development programs. Watch the full video in the link below.

Thank you to our staff scientist, Naveen Kumar R., PhD, for explaining how our automatic peptide synthesizer helps power our first- and best-in-class peptide therapeutics research!

@BiotechTV Thanks again for stopping by, @bradloncar and the @biotechTV team!

𝐅𝐫𝐨𝐦 𝐭𝐡𝐞 𝐁𝐚𝐲 𝐀𝐫𝐞𝐚: @ProtagonistTx has two medicines in front of FDA right now - we discuss the expertise in peptide based drug development that has enabled them to get to this point. $PTGX Full video: biotechtv.com/post/protagoni…

Our Protagonist team had a wonderful time gathering together to ring in the Year of the Horse. We wish all celebrating the Lunar New Year a healthy, happy, and prosperous year ahead! 🐎🧧

Happy International Day of Women and Girls in Science! 🔬 🧪 We thank our amazing team of scientists for all they do to make an impact in the world of peptide drug discovery and development.

Protagonist Therapeutics stands united with cancer patients, caregivers, physicians, and researchers in the global fight against cancer. The #WorldCancerDay theme, "United by Unique," reminds us that everyone's cancer journey is different, and meaningful progress depends on all of us to do our part. For the past decade, our team has been committed to advancing research for polycythemia vera (PV), a rare blood cancer with significant unmet needs. Through bold science and collaboration, we're committed to reshaping what the future can look like for those affected by PV.

That's a wrap for #JPM26! Thanks to all who connected with us this week. On Tuesday, @ProtagonistCEO Dinesh V. Patel, PhD shared pipeline updates for icotrokinra and rusfertide, with NDAs submitted for both. We’re looking ahead to more pipeline updates this year, including progress with PN-881 (oral IL-17, psoriasis) and PN-477 (multi-agonist obesity program). A recording of our presentation is available here: protagonist-inc.com/protagonist-at…

Join us next week as our @ProtagonistCEO, Dinesh V. Patel, PhD, provides a company overview and hosts one-on-one meetings at #JPM26 View our press release for more details and access to the webcast: feeds.issuerdirect.com/news-release.h…

Takeda and Protagonist Therapeutics have announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Read more in our latest press release: bit.ly/4sqgV03

Happy New Year from all of us at Protagonist Therapeutics! As the clock strikes midnight, we enter 2026 with gratitude towards our team, collaborators, and the patient community who inspire our work every day. We remain committed to delivering new options for patients as we strive toward important progress on the horizon.

Happy holidays from Protagonist Therapeutics! Warmest wishes to you and yours this holiday season ❄️